---
title: "Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296400919.md"
description: "Incyte Corp. (INCY) shares rose 4.05% to $128.47 on Wednesday, outperforming the broader market but underperforming key competitors like Alnylam and Bio-Techne. The stock closed 3.11% below its 52-week high of $132.60. Trading volume was lower than the 50-day average, indicating mixed relative performance despite daily gains."
datetime: "2026-08-19T21:02:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296400919.md)
  - [en](https://longbridge.com/en/news/296400919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296400919.md)
generator: "portal-rs"
---

# Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) advanced 4.05% to $128.47 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.21% to 7,707.98 and the Dow Jones Industrial Average rising 0.22% to 53,463.05.

Incyte Corp. closed 3.11% short of its 52-week high of $132.60, which the company reached on July 28th.

The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 6.12% to $242.61, Bio-Techne Corp. (TECH) rose 0.36% to $72.48, and BioMarin Pharmaceutical Inc. (BMRN) rose 3.49% to $69.33.

Trading volume (1.6 M) remained 347,803 below its 50-day average volume of 1.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 19, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

08-19-26 1702ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [What Does Incyte (INCY) Medicare Deal Mean For Future Drug Pricing Risk?](https://longbridge.com/en/news/298140297.md)
- [55,370 Shares in Incyte Corporation $INCY Bought by Summit Global Investments](https://longbridge.com/en/news/295999395.md)
- [Incyte Says It's No Longer A One-Drug Story](https://longbridge.com/en/news/294105383.md)
- [Incyte Corporation $INCY Shares Acquired by Corient Private Wealth LLC](https://longbridge.com/en/news/291026866.md)
- [Incyte expects Opzelura to cross $1B in 2026](https://longbridge.com/en/news/294223769.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**